Clinical Trial Update: Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing a Yttrium-90 labeled anti-CD25 monoclonal antibody plus BEAM chemotherapy conditioning for patients with primary refractory o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Carmustine (carmustine)
• Etoposide (Etoposide)
• Melphalan (Melphalan)
• Yttrium-90 labeled anti-CD25 monoclonal antibody

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Status: RECRUITING